058820 — CMG Pharmaceutical Share Price
Last trade - 00:00- KR₩83bn
- KR₩134bn
- KR₩105bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.41 | ||
| Price to Tang. Book | 0.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.68% | ||
| Return on Equity | 2.31% | ||
| Operating Margin | -5.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 69,475.5 | 82,197.41 | 93,906.68 | 99,099.73 | 105,229.18 | n/a | n/a | 10.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +72.37 | n/a | n/a | -53.5 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CMG Pharmaceutical Co Ltd is a Korea-based company primarily engaged in the manufacturing and sales of pharmaceuticals. The Company primarily engages in the research, development, production, and sales of pharmaceuticals and health functional foods. In addition to pharmaceuticals, the Company also engages in the research and development of new and improved drugs, including anticancer drugs, anti-aging drugs, ophthalmology drugs, health functional foods, as well as mom and baby products.
Directors
- Jeong Ho Kim CEO (56)
- Gyeong Wuk Yoon VPR (46)
- Yin Su Park OTH (70)
- Jun Won Choi DRC (48)
- Jong Guk Song DRC (52)
- Tae Gyu Son NID (62)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- August 1st, 2001
- Public Since
- August 31st, 2001
- No. of Shareholders
- 35,326
- No. of Employees
- 248
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 148,123,556
- Address
- 3F, 170, Hakdong-ro, Gangnam-gu, SEOUL, 06112
- Web
- http://cmgpharma.co.kr/
- Phone
- +82 318817600
- Auditors
- Seowoo Accounting Corporation
Latest News for 058820
Upcoming Events for 058820
CMG Pharmaceutical Co Ltd Reverse Split For 058820.KQ - Ratio 1-10
CMG Pharmaceutical Co Ltd Annual Shareholders Meeting
Similar to 058820
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:00 UTC, shares in CMG Pharmaceutical are trading at KR₩562. This share price information is delayed by 15 minutes.
Shares in CMG Pharmaceutical last closed at KR₩562 and the price had moved by -69.36% over the past 365 days. In terms of relative price strength the CMG Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -77.24% over the past year.
There is no consensus recommendation for this security.
Find out moreCMG Pharmaceutical does not currently pay a dividend.
CMG Pharmaceutical does not currently pay a dividend.
CMG Pharmaceutical does not currently pay a dividend.
To buy shares in CMG Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩562, shares in CMG Pharmaceutical had a market capitalisation of KR₩83bn.
Here are the trading details for CMG Pharmaceutical:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 058820
Based on an overall assessment of its quality, value and momentum CMG Pharmaceutical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CMG Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -68.3%.
As of the last closing price of KR₩562, shares in CMG Pharmaceutical were trading -59.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CMG Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩562.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CMG Pharmaceutical's management team is headed by:
- Jeong Ho Kim - CEO
- Gyeong Wuk Yoon - VPR
- Yin Su Park - OTH
- Jun Won Choi - DRC
- Jong Guk Song - DRC
- Tae Gyu Son - NID